How Is Artificial Intelligence Transforming the Medical Diagnosis?


Artificial intelligence (AI) transforms according to the interaction, consumer information, and goods and services across industries. In the healthcare industry, AI is already changing patients’ experiences, how clinicians practice medicine, and how the pharmaceutical industry operates.

Although, Artificial Intelligence plays an important role in different aspects of medical diagnosis like medical decision making, management, automation, admin, and workflows. It can be used to diagnose cancer, triage critical findings in medical imaging, acute flag abnormalities, help radiologists prioritize life-threatening cases, diagnose cardiac arrhythmias, predict stroke outcomes, and help manage chronic diseases.

Since the, 1970s diagnostics and treatment have been the prime focus of AI, as MYCIN was developed at Stanford for diagnosing blood-borne bacterial infections. MYCIN and other early rule-based systems showed promise for diagnosing and treating disease accurately but were not adopted for clinical practice. They were not substantially better than human diagnosticians, and they were poorly integrated with clinical workflows and medical record systems.

AI is a rich realm of data, algorithms, analytics, deep learning, neural networks, and insights that is growing and adapting to the needs of the healthcare industry and its patients. Although, over the past few years, artificial intelligence in medical care has reduced the extreme pressures felt by the medical industry and is constantly working to evolve in diagnostics. Recently IBM’s Watson received considerable attention in the media for its focus on precision medicine, particularly cancer diagnosis and treatment. As Watson employs a combination of machine learning and NLP capabilities. However, AI seems to be still developing and soon a part of the healthcare diagnostic industry.

To know about: -

·         Types of AI of Relevance to Healthcare Diagnostics

·         AI Applications in Diagnostics

·         AI Related Developments in Diagnostics

·         Future of AI in Diagnoses

·         How Can IEBS Help You?

Please visit: https://www.iebrain.com/how-is-artificial-intelligence-transforming-the-medical-diagnosis/

About Ingenious e-Brain Solutions: -

Ingenious e-Brain Solutions provides high-quality, customized, and cost-effective Technology Intelligence, Business Intelligence, and Intellectual Property Intelligence solutions to industry leaders, and innovative companies across the globe. Innovation, knowledge, and transparency form the basis of our company’s mission and vision. Along with cost benefits, we provide highest quality results ensuring fool-proof confidentiality and security. We are an ISO certified company with offices in India and USA.

Ingenious e-Brain Solutions has a strong team of analysts, and subject matter experts with domain proficiency which is devoted to help clients grow. Our highly qualified professionals offer tailored, value-added and cost-effective services to our clients. We believe in building long term relationships with our clients who include national and international corporations, Fortune 500 companies, world’s leading research institutes and universities as well as independent inventors.

Get in Touch: -
India Office
207-208 Welldone TechPark, Sohna Road
Sector 48, Gurugram, Haryana 122018, India
+91 124 429 4218

Email: -
queries@iebrain.com

Comments

Post a Comment

Popular posts from this blog

Hybrid Meat Analogues – A Middle Ground between Plant-based & Traditional Meat

Image
I n the context of semi-vegetarian choices, hybrid meat analogues are emerging as an alternative to traditional meat products. These are produced using blends of plant and animal ingredients in varying proportions to provide a meaty taste and texture, with the added nutritional benefits from plants. Compared to plant-based alternatives, hybrid analogues such as burgers, sausages, meatballs, and mince have the potential to reduce GHG emissions by 32% if 50% of meat is replaced by plant proteins. The development of hybrid meat analogues begets opportunities and challenges due to the alterations in technical & sensory properties (texture, appearance, taste, etc.) of the meat matrices caused by plant portion. Technical challenges Major technical challenge faced while blending plant-based proteins with meat proteins is the formation of elastic gels through the enclosure of water and fat particles in the protein network upon heating due to the high emulsifying capacity of myofibrilla...
Read more

IEBS Broadening its Horizons Digitally by Allying with Scientist.com as a Registered Supplier

Image
It is a moment of pride for Ingenious e-Brain Solutions (IEBS) that it has become an affiliated supplier of Scientist.com¬—a renowned digital healthcare research platform. Artificial Intelligence (AI) and digitalization are transcending all technologies and have revolutionized how industries operate. Therefore, IEBS has attempted to grow its digital presence by registering with Scientist.com. As the latter is solely a healthcare domain platform, we offer one element from our extensive list of business consulting solutions at Scientist.com. Here, we deliver healthcare-related latest technological & real-time business insights, emphasize potential opportunities for business propulsion, and provide innovative & strategic enterprise solutions on this platform, particularly for pharmaceuticals, biotechnology, medical technology companies, and clinical research organizations. Scientist.com is an inclusive research platform—with a global network exceeding 4,000 suppliers—encouragi...
Read more

Envisioning the Dual Repercussions of FDA’s Accelerated Approval Pathway

Image
Clinical trials are comprehensive research studies conducted to ensure that recently developed medical interventions, including novel drugs, surgical & other devices, and treatments/ therapies, are safe and effective for human use before commercialization. These trials provide evidence for regulatory bodies like the US Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, UK’s Medicines and Healthcare Products Regulatory Agency, and China’s National Medical Products Administration (NMPA) to ensure that a specific medical intervention is safe for the public use, begets limited adverse effects, and meets quality standards. However, it takes 10 to 15 years or even more to complete all three clinical trial phases before reaching the licensing stage. Thus, FDA introduced accelerated or expedite approvals to pace up the approval of drugs that treat severe conditions and address unmet medical needs. Before proceeding with the pros and cons of the FDA’s expe...
Read more